Puma Biotechnology Puma Biotechnology acquires and develops innovative products for the treatment of various forms of cancer. | Takeda Takeda Pharmaceutical is a biopharmaceutical company engaged in the research, development, production, and commercialization of pharmaceutical products. | Ascendis Pharma Ascendis Pharma is a biopharmaceutical company that specializes in endocrinology and oncology. | ||
Founding Date | Founding Date 2010 | Founding Date 1781 | Founding Date 2000 | Founding Date 2007 |
Type | Type Public | Type Public | Type Public | Type Public |
Tags | ||||
Locations | Locations Los Angeles, US HQ | Locations Stockholm, SE HQ Stockholm, SE Los Altos, US Mountain View, US Waltham, US | Locations Hellerup, DK HQ Heidelberg, DE Palo Alto, US | |
Employees | Employees 27214% decrease | Employees 49,281 | Employees 678% increase | Employees 879 |
Valuation ($) | Valuation ($) 130 m | Valuation ($) 45.8 b | Valuation ($) 44.7 m | Valuation ($) 8.7 b |
Financial | ||||
Revenue (est.) | Revenue (est.) $235.6m (FY, 2023) | Revenue (est.) ¥4.3t (FY, 2024) | Revenue (est.) kr35.2m (FY, 2023) | Revenue (est.) €266.7m (FY, 2023) |
Cost of goods | Cost of goods $62.7m (FY, 2023) | Cost of goods ¥698.7b (FY, 2024) | Cost of goods (kr1.1m) (FY, 2023) | Cost of goods €41.9m (FY, 2023) |
Gross profit | Gross profit $173m (FY, 2023) | Gross profit ¥3.6t (FY, 2024) | Gross profit kr42.6m (FY, 2023) | Gross profit €224.8m (FY, 2023) |
Net income | Net income $21.6m (FY, 2023) | Net income ¥144.2b (FY, 2024) | Net income (kr249.1m) (FY, 2023) | Net income (€481.4m) (FY, 2023) |
Funding | ||||
Total funding raised | Total funding raised $ 172m | Total funding raised $ 57.8m | Total funding raised N/A | Total funding raised $ 85.8m |